Home/Nanobiotix/Bart Van Rhijn
BV

Bart Van Rhijn

Chief Financial and Business Officer

Nanobiotix

Therapeutic Areas

Nanobiotix Pipeline

DrugIndicationPhase
NBTXR3Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)Phase III
NBTXR3 + anti-PD-1Solid TumorsPhase I
Curadigm Platform ProgramsUndisclosedDiscovery/Preclinical